• TriSalus Life Sciences posted Q2 revenue of $11.4 million, up 1.7% from the prior-year period.
• Operating loss widened to $9.8 million from $7.3 million, on higher sales and marketing costs tied to commercial expansion.
• Net loss available to common stockholders was $9.2 million; loss per share narrowed to $0.16 from $0.27.
• Gross margin rose 2.9 percentage points to 86.8%, due to a lower cost per TriNav unit.
• Maintained full-year 2026 revenue guidance of $54 million to $57 million; cash and cash equivalents were $46.3 million at June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-054264), on August 06, 2026, and is solely responsible for the information contained therein.